AstraZeneca vaccine program unlikely to be shelved – Clot risk not high enough

Original article by Tamsin Rose, Kieran Rooney
Herald Sun – Page: 11 : 6-Apr-21

The Australian Technical Advisory Group on Immunisation will meet on 7 April to discuss the future rollout of AstraZeneca’s COVID-19 vaccine. A 44-year-old Melbourne man was recently admitted to hospital with a rare blood clotting condition after receiving the vaccine. Acting Chief Medical Officer Michael Kidd says it is "likely" that the case is linked to the vaccine, but he adds that there is no evidence to suggest that the risk is sufficiently high to halt the rollout. Kidd stresses that the vaccination program is necessary as Australia will remain vulnerable to future outbreaks, particularly as its international borders re-open.

CORPORATES
AUSTRALIAN TECHNICAL ADVISORY GROUP ON IMMUNISATION, AUSTRALIA. DEPT OF HEALTH, ASTRAZENECA PLC

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s